Related Experiment Video
Updated: May 21, 2026
05:47
Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
US payer perspectives on evidence for formulary decision making
Anthony Wang1, Ronald J Halbert, Tiffany Baerwaldt
1PriceSpective, Los Angeles, CA, USA. awang@pricespective.com
The American Journal of Managed Care
|June 15, 2012
Summary
Commercial payers desire more comparative effectiveness research (CER) for formulary decisions but find current CER lacking, especially in oncology. They seek collaboration to improve research and treatment guidelines for better healthcare outcomes.
Area of Science:
- Health Services Research
- Health Economics
- Pharmaceutical Policy
Background:
- Comparative Effectiveness Research (CER) plays a crucial role in healthcare decision-making.
- Understanding the perspective of commercial payers on CER is vital for effective formulary management.
- Previous research has not adequately explored how commercial payers utilize CER in their decision-making processes.
Purpose of the Study:
- To describe the utilization and valuation of Comparative Effectiveness Research (CER) by US commercial payers.
- To understand how CER influences formulary decision-making across different disease states.
- To identify payer needs and preferences regarding CER study design and application.
Main Methods:
- Qualitative interviews were conducted with 20 medical and pharmaceutical directors from national and regional health plans.
- Participants were involved in pharmaceutical and therapeutics committees.
- Payer perspectives on the usefulness of various CER study types were assessed across different disease states and market conditions, followed by thematic content analysis.
Main Results:
- Commercial payers expressed interest in a wide array of CER study types.
- Payers reported dissatisfaction with the current state of CER and expressed a desire to collaborate with research groups.
- The value placed on CER was lower in oncology compared to other disease states due to management limitations for oncology therapies.
Conclusions:
- Policy makers should involve commercial payers in the development of CER to enhance formulary design.
- Collaborative efforts in creating research and treatment guidelines are recommended to better leverage CER.
- Engaging payers can lead to more effective healthcare provision and improved formulary processes.
Related Concept Videos
01:21Methods of Documentation III: PIE
Problem-intervention-evaluation (PIE) is a systematic approach to documentation used in healthcare settings for clinical decision-making and patient care planning. It is a structured approach to organizing patient data based on problems, interventions, and evaluations. Here's a breakdown of its key features and considerations:
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:09Decision Making: P-value Method
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
01:15Methods of Documentation VI: Case Management Model
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
For example, a patient with a chronic illness...
01:30Health Information Technology and Healthcare Information System
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...